The public awareness of gene patenting has grown because of the most recent court ruling on the BRCA patents held by Myriad Genetics (Association for Molecular Pathology v. United States Patent and Trademark Office, US District Court, Southern District of NY, March 29, 2010). Many scientists and professional societies have advocated a change in the practice of patenting and licensing individual human genes, but most of the discussion has focused on the mutational analysis of single genes. In the past decade, numerous multimarker microarray and proteomic assays with potential clinical use have been developed. Each of these assays contains dozens of markers that are all required for clinical utility; however, the creators of these assays do not typically address the potential problems that may occur when one or more of the biomarkers of interest have already been patented and licensed by another party. The barrier to utilizing a technology that contains multiple pieces of intellectual property assigned to multiple owners is reminiscent of the predicted "tragedy of the anticommons" (1 ) . The concept of the tragedy of the anticommons in biomedical research was described a decade ago as the underutilization of a scarce resource with too many overlapping owners (1 ) . It is an adaptation of the "tragedy of the commons" explanation for the opposite type of problems, which occur when shared public resources are overused because no individual has the ownership authority to prevent use by another. The result of this unrestricted use was hypothesized to be the cause of overpopulation, pollution, deforestation, and depleted fisheries (2 ) . As an example of the tragedy of the commons, imagine 2 sheepherders overgrazing the same public field (a common) until the land was overused and could no longer support any livestock. In a "microarray anticommons," we can imagine a single multimarker assay that uses multiple biomarkers that are patented and licensed to multiple competing parties. Theoretically, because there are multiple competing parties, the commercialization of the assay does not occur. Indeed, the tragedy of the microarray anticommons is that multimarker assays such as microarrays will have barriers to clinical implementation if they use patented biomarkers that cannot be licensed.
The potential patent problem of multimarker assays is exemplified by a recent multi-institutional study that correlated a gene expression profile of patients' tumors with the response to chemotherapies (3 ) . This study created a gene expression profile that correlates with mutations or defects in BRCA1 2 (breast cancer 1, early onset) and BRCA2 (breast cancer 2, early onset) activity (BRCAness profile). 3 The study specifically examined platinum agents, as well as a new category of targeted chemotherapeutics that are inhibitors of poly(ADP-ribose) polymerase (PARP). Platinum agents and PARP inhibitors have previously been shown to have greater effectiveness in patients with BRCA1/2 mutations. The BRCAness profile of 60 genes was found to have clinical promise in determining chemotherapy, independent of examining the sequences of the BRCA1 and BRCA2 genes. The potential microarray anticommons was demonstrated by searching the United States Patent and Trademark Office database for any issued US patents that claim the use of the genes and/or their expressed mRNA contained in the BRCAness profile (http://www.uspto.gov; accessed July 1, 2010). Of the 60 genes in the BRCAness profile, 7 genes and/or their nucleic acid sequence have previously issued patents ( Table 1) . Most of the patents for these genes have some description of an assay for use in disease, and several describe use in oncology applications. Of particular interest are 3 of the genes (MGST3, microsomal glutathione S-transferase 3; GBP1, guanylate binding protein 1, interferon-inducible, 67kDa; MTAP, methylthioadenosine phosphorylase), which have patents that specifically claim the use of nucleotide sequences in hybridization assays. Because the final outcome of the Association for Molecular Pathol-ogy lawsuit is still unknown, the impact of these patented genes on the BRCAness profile should be considered. The loss of these 7 genes from the 60-gene panel will likely diminish the utility of the BRCAness profile and may render it unusable.
Given that the ultimate goal of developing multimarker tests such as the BRCAness profile is clinical use, the potential of assay inoperability due to an inability to license individual biomarkers should be considered from the earliest stages of development. Ideally, a screen for patented biomarkers should occur before a final algorithm is selected. Discovering that key biomarkers are already patented and cannot be licensed during a clinical trial is inopportune. As predicted by the tragedy of the anticommons, multiple owners of patents in the same area of interest may impede commercialization and clinical utilization (1 ). Multimarker tests such as gene expression microarrays are certainly powerful tools in subclassifying biological samples, but patenting issues should be anticipated to facilitate the transition of these tools into platform technologies that can be used in the clinical laboratory.
An analysis of the BRCAness profile indicates several potential solutions to this potential microarray anticommons. First, 88% of the genes were not claimed in any issued US patent. This finding creates hope that multimarker panels may be designed to avoid existing intellectual property; perhaps the BRCAness profile could be redesigned to omit the 7 genes identified in this patent analysis. Second, the majority of the patents (4 of 7) were assigned to universities or other nonprofit organizations (Table 1) . Although the standard practice in the US is for the exclusive licensing of patents, perhaps these institutions may cross-license with one another. Third, the concept of a gene patent pool should be revisited. A decade ago, the potential for the anticommons was recognized, and gene patent pooling was proposed as a potential solution (4, 5 ) . Patent pools for genes have been envisaged as a service run by nonprofit organizations that would manage the licensing of patents from both nonprofit and commercial entities. For biomedical research institutions seeking to develop new clinical tools, a patent pool of genes could provide a single licensing source for developing new Perhaps the recent ruling on BRCA genes will be upheld in the US judicial system. If not, researchers and developers of clinical multimarker assays should be prepared to deal head-on with the issues of biomarker and gene patents. Over the past 2 decades, the utility of multimarker proteomic and gene expression assays as research tools has been well established. There are now several clinical microarray-based assays available in the European and US markets. As technical issues of quality control are solved, these complex assays will inevitably become more clinically useful and commonplace; however, the large number of analytes that power these assays is also the potential Achilles' heel in terms of commercialization. By embracing issues of intellectual property in the earliest stages of developing a multimarker assay, perhaps a microarray anticommons can be avoided. 
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